Literature DB >> 30190886

Advancements in unresectable melanoma: a multidisciplinary perspective.

Mary-Kate Malecek1,1, June K Robinson2,2, Karl Bilimoria3,3, Jennifer N Choi2,2, Jaehyuk Choi2,2, Pedram Gerami2,2, Timothy Kruser4,4, Timothy Kuzel5,5, Mary Martini2,2, Jonathan B Strauss3,3, Jeffrey Wayne3,3, Jeffrey Sosman5,5, Sunandana Chandra5,5.   

Abstract

Entities:  

Keywords:  clinical trials; immunotherapy; melanoma

Year:  2016        PMID： 30190886      PMCID： PMC6094606          DOI： 10.2217/mmt-2016-0003

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  26 in total

1.  Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Authors:  Alexander M Menzies; Lauren E Haydu; Lydia Visintin; Matteo S Carlino; Julie R Howle; John F Thompson; Richard F Kefford; Richard A Scolyer; Georgina V Long
Journal:  Clin Cancer Res       Date:  2012-04-24       Impact factor: 12.531

2.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

Authors:  Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean-Jacques Grob; Vanna Chiarion-Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Suzanne Swann; Jeffrey J Legos; Fan Jin; Bijoyesh Mookerjee; Keith Flaherty
Journal:  Lancet       Date:  2015-05-31       Impact factor: 79.321

3.  Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article.

Authors:  Donald N Liew; Hideyuki Kano; Douglas Kondziolka; David Mathieu; Ajay Niranjan; John C Flickinger; John M Kirkwood; Ahmad Tarhini; Stergios Moschos; L Dade Lunsford
Journal:  J Neurosurg       Date:  2010-06-04       Impact factor: 5.115

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Immunologic correlates of the abscopal effect in a patient with melanoma.

Authors:  Michael A Postow; Margaret K Callahan; Christopher A Barker; Yoshiya Yamada; Jianda Yuan; Shigehisa Kitano; Zhenyu Mu; Teresa Rasalan; Matthew Adamow; Erika Ritter; Christine Sedrak; Achim A Jungbluth; Ramon Chua; Arvin S Yang; Ruth-Ann Roman; Samuel Rosner; Brenna Benson; James P Allison; Alexander M Lesokhin; Sacha Gnjatic; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

6.  Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma.

Authors:  Travis B Kidner; Donald L Morton; Delphine J Lee; Mary Hoban; Leland J Foshag; Roderick R Turner; Mark B Faries
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

7.  100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.

Authors:  Vivian Y Shi; Khiem Tran; Forum Patel; Jonathan Leventhal; Thomas Konia; Maxwell A Fung; Reason Wilken; Miki Shirakawa Garcia; Sarah D Fitzmaurice; Jayne Joo; Arta M Monjazeb; Barbara A Burrall; Brett King; Steve Martinez; Scott D Christensen; Emanual Maverakis
Journal:  J Am Acad Dermatol       Date:  2015-08-07       Impact factor: 11.527

8.  BCG immunotherapy of malignant melanoma: summary of a seven-year experience.

Authors:  D L Morton; F R Eilber; E C Holmes; J S Hunt; A S Ketcham; M J Silverstein; F C Sparks
Journal:  Ann Surg       Date:  1974-10       Impact factor: 12.969

9.  Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy.

Authors:  Giada Heber; Doris Helbig; Iris Pönitzsch; Tino Wetzig; Wolfgang Harth; Jan-Christoph Simon
Journal:  J Dtsch Dermatol Ges       Date:  2009-02-23       Impact factor: 5.584

10.  Treatment of in-transit melanoma with intralesional bacillus Calmette-Guérin (BCG) and topical imiquimod 5% cream: a report of 3 cases.

Authors:  Nour Kibbi; Stephan Ariyan; Mark Faries; Jennifer N Choi
Journal:  J Immunother       Date:  2015 Nov-Dec       Impact factor: 4.456
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.